title: Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X).
abstract: Ten children with Langerhans cell histiocytosis (histiocytosis X) either resistant to or intolerant of corticosteroids received etoposide (VP16). Nine responded. In one instance, partial diabetes insipidus was temporarily reversed. There was no major toxicity. Etoposide should be seriously considered as therapy for patients with LCH in whom the toxicity/benefit ratio of steroid therapy is unacceptably high.
authors: Department of Haematology & Oncology, Hospital for Sick Children, London, England.
authors: V
authors: V
authors: Broadbent
authors: J
authors: J
authors: Pritchard
authors: E
authors: E
authors: Yeomans
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D013256:Steroids / Q000009:adverse effects
chemical_list: D013256:Steroids; D005047:Etoposide